Tumour-induced osteomalacia: 18 months of 2-weekly burosumab treatment

SUMMARY: Tumour-induced osteomalacia (TIO) is due to an overproduction of fibroblast growth factor 23 (FGF23) by mesenchymal tumours, causing hypophosphatemia, osteomalacia and muscle weakness. TIO is usually cured by tumour resection, but neoplasms may be unidentifiable and unresectable or the pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Aliberti, L, Gagliardi, I, Pontrelli, M, Zatelli, M C, Ambrosio, M R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2023
Materias:
Novel Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986401/
https://www.ncbi.nlm.nih.gov/pubmed/37931408
http://dx.doi.org/10.1530/EDM-22-0317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986401/
https://www.ncbi.nlm.nih.gov/pubmed/37931408
http://dx.doi.org/10.1530/EDM-22-0317

Ejemplares similares